Close Menu

NEW YORK (GenomeWeb) – Ambry Genetics said this week that it is adding a new feature to its hereditary cancer risk testing menu: a service called +RNAinsight, which adds RNA sequencing of a group of target genes to the company's existing DNA sequencing panel.

The new offering doesn’t change the cost or turnaround time, which is the same as for the company’s DNA-only testing, said Brigette Davis, Ambry's senior VP of research and development.  

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.